Cramer's 'Mad Money' Recap: Get In the GameStop

Although it reported better-than-expected earnings, it guided down "rather low," Cramer said. On top of that, Align announced its CFO is leaving, and the stock dropped nine points.

"Its growth story is in jeopardy," he said. "This is a big mea culpa" and there is no reason to hang on to it here.

Moving on, Hansen Medical has gone up and it's time to walk away from it now, Cramer advised. "Sell all of it."

Also, as lululemon (LULU Quote) and Research In Motion (RIMM Quote) are both up more than 50% since he recommended them, "sell half of your positions" in them, he said.

There's been some selling action in Celgene (CELG Quote); however, Cramer said he still thinks it's a triple buy.

To clear things up, he welcomed Bob Hugin, Celgene's president and COO, to the show and asked about the company's Revlimid rollout in Europe.

Hugin said he believes sales were "pretty solid and strong," but people expected more. However, Europe is not like the U.S., he explained. "You roll out in one country at a time" and so far the only major European country it's rolled out in is Germany. The prospects in Europe, he said, "are strong."

Further, the actual revenue didn't reflect the full underlying demand for Revlimid, even in the U.S., he continued. "Things are looking very promising."